Cardiometabolic disorders were originally thought to be driven primarily by changes in lipid metabolism that cause the accumulation of lipids in organs, thereby impairing their function. Thus, in the setting of cardiovascular disease, statins — a class of lipid-lowering drugs — have remained the frontline therapy. In the past 20 years, seminal discoveries have revealed a central role of both the innate and adaptive immune system in driving cardiometabolic disorders. As such, it is now appreciated that immune-based interventions may have an important role in reducing death and disability from cardiometabolic disorders. However, to date, there have been a limited number of clinical trials exploring this interventional strategy. Nonetheless, elegant preclinical research suggests that immune-targeted therapies can have a major impact in treating cardiometabolic disease. Here, we discuss the history and recent advancements in the use of immunotherapies to treat cardiometabolic disorders.

心脏代谢紊乱最初被认为主要是由脂质代谢的变化引起的，脂质代谢的变化导致器官中脂质的积累，从而损害其功能。因此，在心血管疾病的背景下，他汀类药物——一类降脂药物——仍然是一线治疗药物。在过去的 20 年里，开创性的发现揭示了先天免疫系统和适应性免疫系统在驱动心脏代谢紊乱方面的核心作用。因此，现在认识到基于免疫的干预措施可能在减少心脏代谢紊乱引起的死亡和残疾方面发挥重要作用。然而，迄今为止，探索这种介入策略的临床试验数量有限。尽管如此，优雅的临床前研究表明，免疫靶向疗法可以对治疗心脏代谢疾病产生重大影响。在这里，我们讨论了使用免疫疗法治疗心脏代谢紊乱的历史和最新进展。